Times: Lilly mulling $1-bil. payout to feds for Zyprexa marketing

Share this article:

An article in The New York Times says that Lilly is considering a $1 billion settlement of a four-year federal investigation into Zyprexa marketing, but the company cast doubt on the Times' reporting.

The settlement would be the largest ever for a federal case involving illegal marketing practices by a pharmaceutical firm, the Times piece said. Lilly is alleged to have promoted the drug, which is approved for treatment of schizophrenia and severe bipolar disorder, for use in patients suffering from mild bipolar disorder and age-related dementia.

In a statement, the company acknowledged receipt of a grand jury subpoena from the Office of the US Attorney for the Eastern District of Pennsylvania seeking documents related to Zyprexa, but cautioned, “know that we disagree with many speculative statements contained in the article in the Times.”

Lilly, the statement said, “is committed to promoting our medications only for approved uses and consistent with all federal and state laws. We disagree with any allegations or suggestions to the contrary.” The firm is cooperating with state and federal investigations, the statement continued, and as part of that, regularly has discussions with the government, but has “no intention of sharing those discussions with the news media, and it would be speculative and irresponsible for anyone to do so.”

The company has already set aside $1.2 billion to settle lawsuits from patients claiming that the weight gain associated with the drug caused them to develop diabetes or other ailments. Lilly has settled more than 25,000 claims related to Zyprexa. Another 1,100 remain unsettled.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...